Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors
Open Access
- 17 September 2016
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (47) , 76565-76576
Abstract
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumorsKeywords
This publication has 44 references indexed in Scilit:
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune EscapeScience Translational Medicine, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Improved structure, function and compatibility for CellProfiler: modular high-throughput image analysis softwareBioinformatics, 2011
- B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cellsNeuro-Oncology, 2009
- Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impairedBlood, 2009
- PD-1 on dendritic cells impedes innate immunity against bacterial infectionBlood, 2009
- The Three Es of Cancer ImmunoeditingAnnual Review of Immunology, 2004
- Prevalence of Lymphocytic Infiltrate in 1400 Pituitary Adenomas.Endocrine Journal, 1998